Metrikler
Yayın
40
Açık Erişim
6
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (30)
SCI-E, SSCI, AHCI (26)
SCI-E, SSCI, AHCI, ESCI (29)
ESCI (3)
Scopus (29)
TRDizin (5)
2024
20241. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
, cilt.34, ss.1359-1365, 2024 (SCI-Expanded, Scopus)
2024
20242. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab
YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.
BIOMOLECULES AND BIOMEDICINE
, cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)
2024
20243. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.
Clinical Genitourinary Cancer
, cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)
2024
20244. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., et al.
Future oncology (London, England)
, cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)
2023
20235. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience
Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., et al.
Journal of Oncological Science
, cilt.9, sa.2, ss.72-78, 2023 (Scopus, TRDizin)
2019
20196. The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival
Sunar V., Ates O., Korcali Aslan A., Karakas Y., Altundag M. K.
ARCHIVES OF RHEUMATOLOGY
, cilt.34, sa.2, ss.141-147, 2019 (SCI-Expanded, Scopus, TRDizin)
2019
20197. The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy
ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., et al.
ANTI-CANCER DRUGS
, cilt.30, sa.3, ss.289-294, 2019 (SCI-Expanded, Scopus)
2018
20188. Behcet's disease and breast cancer: A case series study
Karatas F., Sahin S., Aytekin A., Erdem G. U., ATEŞ Ö., Ozisik Y., et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
, cilt.14, sa.6, ss.1184-1190, 2018 (SCI-Expanded, Scopus)
2018
20189. Association between androgen receptor status and prognosis in triple negative breast cancer
Sunar V., Dogan H. T., Sarici F., ATEŞ Ö., AKIN S., BAŞPINAR B., et al.
JOURNAL OF BUON
, cilt.23, sa.5, ss.1325-1330, 2018 (SCI-Expanded, Scopus)
2018
201810. Primary gastric choriocarcinoma
Ates O., Altundag K., Gullu I.
JOURNAL OF BUON
, cilt.23, sa.2, ss.534, 2018 (SCI-Expanded, Scopus)
2017
201711. Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers
Karakas Y., KERTMEN N., LAÇİN Ş., Aslan A., DEMİR M., ATEŞ Ö., et al.
JOURNAL OF BUON
, cilt.22, sa.3, ss.623-627, 2017 (SCI-Expanded, Scopus)
2017
201712. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients
Karatas F., Erdem G. U., Sahin S., Aytekin A., YÜCE D., SEVER A. R., et al.
BREAST
, cilt.32, ss.237-244, 2017 (SCI-Expanded, Scopus)
2017
201713. The short-term safety of adjuvant paclitaxel plus trastuzumab - A single centre experience
ATEŞ Ö., Sunar V., Aslan A., Karatas F., Sahin S., Altundag K.
JOURNAL OF BUON
, cilt.22, sa.2, ss.320-324, 2017 (SCI-Expanded, Scopus)
2017
201714. Evaluation of risk factors for the recurrence of colorectal polyps and colorectal cancer
ATEŞ Ö., SİVRİ B., KILIÇKAP S.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.47, sa.5, ss.1370-1376, 2017 (SCI-Expanded, Scopus, TRDizin)
2016
201615. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience
Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.
JOURNAL OF BUON
, cilt.21, sa.4, ss.826-831, 2016 (SCI-Expanded, Scopus)
2016
201616. Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients
Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R., AKIN S., et al.
JOURNAL OF BUON
, cilt.21, sa.4, ss.799-808, 2016 (SCI-Expanded, Scopus)
2016
201617. Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer
Karatas F., Sahin S., Erdem G. U., ATEŞ Ö., BABACAN T., AKIN S., et al.
JOURNAL OF BUON
, cilt.21, sa.4, ss.851-858, 2016 (SCI-Expanded, Scopus)
2016
201618. Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors
ATEŞ Ö., SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., et al.
SPRINGERPLUS
, cilt.5, 2016 (SCI-Expanded, Scopus)
2016
201619. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.
JOURNAL OF BUON
, cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus)
2016
201620. When should we give aromatase inhibitors for insomnia; early in the day or after dinner?
ATEŞ Ö., Sunar V., SEVER A. R., Altundag K.
JOURNAL OF BUON
, cilt.21, sa.2, ss.521, 2016 (SCI-Expanded, Scopus)
2016
201621. Primary amyloidosis presenting intrahepatic cholestasis and fulminant hepatic failure
Ates O., KÖSEMEHMETOĞLU K., Guner G., Bayraktar Y.
ITALIAN JOURNAL OF MEDICINE
, cilt.10, sa.1, ss.71-73, 2016 (ESCI, Scopus)
2016
201622. Primary hepatic Ewing sarcoma: a very infrequent case report
ATEŞ Ö., Basel F. B., Bozdogan N., Aksel B., Oksuzoglu O. B.
ITALIAN JOURNAL OF MEDICINE
, cilt.10, sa.1, ss.67-70, 2016 (ESCI, Scopus)
2016
201623. Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment
ATEŞ Ö., GÜVEN D. C., BABACAN T., Sunar V., Sarici F., AKSOY S., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.4, ss.206-214, 2016 (SCI-Expanded, Scopus, TRDizin)
2015
201524. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.
TUMORI J
, cilt.101, sa.4, ss.418-423, 2015 (SCI-Expanded, Scopus)
2015
201525. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis
BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.
JOURNAL OF BUON
, cilt.20, sa.2, ss.479-486, 2015 (SCI-Expanded, Scopus)
2015
201526. Molecular subtypes in patients with inflammatory breast cancer; A single center experience
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus)
2015
201527. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer
Buyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.22-27, 2015 (SCI-Expanded, Scopus)
2015
201528. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab
ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.
JOURNAL OF BUON
, cilt.20, sa.1, ss.349, 2015 (SCI-Expanded, Scopus)
2011
201129. The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting
KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G.
HEPATO-GASTROENTEROLOGY
, cilt.58, sa.105, ss.208-212, 2011 (SCI-Expanded, Scopus)
2009
200930. Paraneoplastic Encephalitis Associated with Anti-Ma2 Antibodies and Mesothelioma-Like Poorly Differentiated Lung Cancer
Bekircan C. E., Eker A., ATEŞ Ö., Oguz K. K.
TURKISH JOURNAL OF NEUROLOGY
, cilt.15, sa.2, ss.98-101, 2009 (ESCI, TRDizin)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2017
20171. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ
KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.
22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2016
20162. The impact of the total size of lesions in multifocal multicentric breast cancer on survival
Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2016
20163. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma
ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2015
20154. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever
ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
20155. Tumor locations significantly affect disease free survival and overall survival
BUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
20156. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
20157. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
20158. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.
Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
20159. Results of the Turkish prospective multi-center study utilizing the 21-gene Oncotype DX assay: Decision impact analysis.
Ozmen V., Atasoy A., Gokmen E., Ozdogan M., Guler E. N., Uras C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201510. Signet ring cell carcinoma of breast: Single center experience.
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)